Breast Cancer News
In this section, access cutting-edge breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
NEW YORK (Reuters Health) - Among women who have been treated for breast cancer, heavier women are more likely to have their disease come back and more likely to die of cancer, according to a new study.
NEW YORK (Reuters Health) - How frequently older women use aspirin and other pain relievers has nothing to do with their chance of developing breast cancer, a large new study suggests.
New evidence suggests that osteonecrosis of the jaw is uncommon after treatment with bisphosphonates or denosumab (Xgeva), a lab-created protein used to prevent bone fractures in cancers that metastasized to the bone. Monitoring oral dental health may prevent or resolve osteonecrosis as a side effect, the study found.
Young age does not independently predict delay in diagnosing breast cancer and has only a modest effect on higher stage disease.
WASHINGTON (Reuters) - Planned Parenthood, a target of U.S. conservatives opposed to its abortion and birth control services, said on Monday it would use $3 million in donations to launch an initiative to fight breast cancer with expanded screenings and education.
(Reuters) - A U.S. federal appeals court has once again affirmed the right of Myriad Genetics Inc to patent two genes linked to breast and ovarian cancer, after the U.S. Supreme Court told it to take another look at the hotly contested case.
Difficulties with general health, chronic conditions, sex and more were shown to be long-term effects of breast cancer treatment for women diagnosed at age 50 or younger.
Results from the international EMILIA study suggest a new effective treatment for HER2 positive metastatic breast cancer, using trastuzumab (Herceptin) linked with the potent chemotherapy DM1.
Postmenopausal women with metastatic, hormone receptor-positive breast cancer may now be treated with everolimus (Afinitor) in combination with exemestane (Aromasin), following FDA’s recent approval of the tablet medicine.
FDA approves pertuzumab (Perjeta) for use in treating HER2 positive metastatic breast cancer when combined with trastuzumab (Herceptin), an anti-HER2 medicine that targets a different part of the HER2 protein, and docetaxel (Taxotere), a type ofchemotherapy.